Skip to main content

Advertisement

Table 3 Identified patient access schemes in the Asian-Pacific region (excluding Australian examples)

From: Patient access schemes in Asia-pacific markets: current experience and future potential

Country Drug Indication Company Payer Type Details Source
South Korea Migraine medications Migraine headaches Not specified National health insurance Financially-based Pharmaceutical companies maintained their PLS status via voluntary price cuts Lee et al. 2012 [22]
Hypertension medications Hypertension Not specified National health insurance Financially-based 285 of the 1226 hypertension drugs instituted price reductions following reassessment of clinical usefulness & price. Drugs were delisted if they failed to show a level of clinical usefulness or if their prices were higher than 80 percentile of the highest price among drugs containing the same ingredients. If the company accepted price cuts, the price was to be lowered to the level of the 80 percentile within 3 years Lee et al. 2012 [22]
Hyperlipidemia medications - therapeutic class Hyperlipidemia Not specified National health insurance Financially-based Pharmaceutical companies maintained their PLS status via voluntary price cuts Lee et al. 2012 [22]
New Zealand Beta-interferon products, glatiramer acetate Multiple sclerosis Bayer PHARMAC Financially-based Extended coverage for a specified number of patients Raftery 2008 [23]
Trastuzumab Breast cancer Roche PHARMAC Financially-based Established separate hospital program to fund distribution of cancer drugs Raftery 2008 [23]
Imatinib Chronic myeloid leukemia Novartis PHARMAC Financially-based Offered overall price reduction Raftery 2008 [23]
Atorvastatin Hypertension Pfizer PHARMAC Financially-based Price volume agreements; manufacturer committed to pay for the drug if the sales exceed a fixed threshold Antonanzas et al. 2011 [24]
  Adalimumab Arthritis Abbott Laboratories NZ Ltd PHARMAC Financially-based Adalimumab spending is probably overstated due to a risk sharing agreement between the sponsor and PHARMAC, which involves rebates paid by the sponsor once Government spending reaches a certain level Access Economics report for Arthritis New Zealand 2010 [25]
  1. HIRA = Health Insurance Review & Assessment Service; PLS = positive list system; PHARMAC = The Pharmaceutical Management Agency.